Adam Fogel

Title: The Innovations of Adam Fogel

Introduction

Adam Fogel is an accomplished inventor based in Watertown, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of inhibitors related to TGFβ. With a total of 3 patents, Fogel's work is paving the way for advancements in treating fibrotic conditions.

Latest Patents

Fogel's latest patents include the development of LTBP complex-specific inhibitors of TGFβ and their uses. These patents disclose inhibitors, such as antibodies and antigen-binding portions, that selectively bind to complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The applications provide methods for using these inhibitors to inhibit TGFβ activation and treat subjects suffering from TGFβ-related disorders, including fibrotic conditions. Additionally, methods for selecting context-dependent or context-independent isoform-specific TGFβ inhibitors for subjects in need are also outlined.

Career Highlights

Adam Fogel is currently associated with Scholar Rock, Inc., where he continues to innovate and contribute to the field. His work is characterized by a strong focus on therapeutic applications that address critical health issues.

Collaborations

Fogel collaborates with notable colleagues, including Thomas Schurpf and Justin W. Jackson. Their combined expertise enhances the research and development efforts at Scholar Rock, Inc.

Conclusion

Adam Fogel's contributions to biotechnology through his patents and collaborations are significant. His work on TGFβ inhibitors holds promise for improving treatments for fibrotic conditions.